Skip to main content
SpringerLink
Log in

Schilddrüsentherapeutika

  • Chapter
Book cover Arzneiverordnungs- Report 2014

  • 1529 Accesses

Zusammenfassung

Krankheiten der Schilddrüse werden mit Schilddrüsenhormonen, Iodsalzen und Thyreostatika behandelt. Die größte Gruppe der Schilddrüsentherapeutika sind die Schilddrüsenhormone, die bei der Schilddrüsenunterfunktion und beim Iodmangelkropf eingesetzt werden. Als zweitgrößte Gruppe folgen die Iodsalze zur Strumaprophylaxe. Wesentlich seltener und weiter langsam abnehmend werden Thyreostatika zur Hemmung der Hormonproduktion bei Schilddrüsenüberfunktion eingesetzt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alexander EK, Marquesee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR (2004) Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 351:241–249

    Article  CAS  PubMed  Google Scholar 

  • Benvenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, Saraceno G, Trimarchi F (2008) Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 18:293–301

    Article  CAS  PubMed  Google Scholar 

  • Bolk N, Visser TJ, Kalsbeek A, van Domburg RT, Berghout A (2007) Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. Clin Endocrinol 66:43–48

    CAS  Google Scholar 

  • Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A (2010) Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med 170:1996–2003

    Article  CAS  PubMed  Google Scholar 

  • Burman K, Hennessey J, McDermott M, Wartofsky L, Emerson C (2008) The FDA revises requirements for levothyroxine products. Thyroid 18:487–490

    Article  PubMed  Google Scholar 

  • Centanni M, Garganol L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, Annibale B (2006) Thyroxine in goiter, helicobacter pylori infection, and chronic gastritis. N Engl J Med 354:1787–1795

    Article  CAS  PubMed  Google Scholar 

  • Cerqueira C, Knudsen N, Ovesen L, Perrild H, Rasmussen LB, Laurberg P, Jørgensen T (2009) Association of iodine fortification with incident use of antithyroid medication – a Danish Nationwide Study. J Clin Endocrinol Metab 94:2400–2405

    Article  CAS  PubMed  Google Scholar 

  • Gärtner R, Reincke M (2008) Substitution von Schilddrüsenhormonen. Internist (Berl) 49:538–544

    Article  Google Scholar 

  • Grozinsky-Glasberg S, Fraser A, Nashoni E, Weizman A, Leibovici L (2006) Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: Meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 91:2692–2699

    Article  Google Scholar 

  • Grussendorf M, Reiners C, Paschke R, Wegscheider K; LISA Investigators (2011) Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 96:2786–2795

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hess SY, Zimmermann MB, Torresani T, Burgi H, Hurrell RF (2001) Monitoring the adequacy of salt iodization in Switzerland: a national study of school children and pregnant women. Eur J Clin Nutr 55:162–166

    Article  CAS  PubMed  Google Scholar 

  • Jonklaas J, Davidson B, Bhagat S, Soldin SJ (2008) Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299:769–777

    Article  CAS  PubMed  Google Scholar 

  • Lind P, Kumnig G, Heinisch M, Igerc C, Mikosch P, Gallowitsch HJ, Kresnik E, Gomez I, Unterweger O, Aigner H (2002) Iodine supplementation in Austria: Methods and results. Thyroid 12:903–907

    Article  CAS  PubMed  Google Scholar 

  • Meng W, Scriba PC (2002) Jodversorgung in Deutschland. Dtsch Ärztebl 99:A2560–A2564

    Google Scholar 

  • Saravanan P, Siddique H, Simmons DJ, Greenwood R, Dayan CM (2007) Twenty-four hour hormone profiles of TSH, free T3 and free T4 in hypothyroid patients on combined T3/T4 therapy. Exp Clin Endocrinol Diabetes 115:261–267

    Article  CAS  PubMed  Google Scholar 

  • Schäffler A (2010) Substitutionstherapie nach Operationen an Schilddrüse und Nebenschilddrüse. Dtsch Ärztebl 107:827–834

    Google Scholar 

  • Schumm-Draeger P-M, Grünwald F (2003) Aspekte der Kombinationstherapie. Dtsch Ärztebl 100:C427–C428

    Google Scholar 

  • Scriba PC, Heseker H, Fischer A (2007) Jodmangel und Jodversorgung in Deutschland – Erfolgreiche Verbraucherbildung und Prävention am Beispiel von jodiertem Speisesalz. Präv Gesundheitsf 2:143–148

    Article  Google Scholar 

  • Soldin OP, Soldin SJ, Pezzullo JC (2003) Urinary idodine percentile ranges in the United States. Clin Chim Acta 328:185–190

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, Hamilton W, Okosieme O, Panicker V, Thomas SL, Dayan C (2014) Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 174:32–39

    Article  CAS  PubMed  Google Scholar 

  • Völzke H, Schwahn C, Kohlmann T, Kramer A, Robinson DM, John U, Meng W (2005) Risk factors for goiter in a previously iodine-deficient region. Exp Clin Endocrinol Diabetes 113:507–515

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mozartstraße 20, 69121, Heidelberg

    Prof. Dr. med. h.c. Reinhard Ziegler

  2. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. h.c. Reinhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ziegler, R., Schwabe, U. (2014). Schilddrüsentherapeutika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43487-1_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43486-4

  • Online ISBN: 978-3-662-43487-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation